Yu U Chen

US Patent:

20230116783, Apr 13, 2023

Filed:

Feb 8, 2021

Appl. No.:

17/798041

Inventors:

- Tampa FL, US
Stephen Bryant LIGGETT - Treasure Island FL, US
David E. KANG - Wesley Chapel FL, US
Yu CHEN - Tampa FL, US
Eric LEWANDOWSKI - Tampa FL, US

International Classification:

A61K 38/17
A61P 25/28
A61K 31/437
A61K 31/496
A61K 31/42

Abstract:

As disclosed herein, β-arrestin1 and β-arrestin2 levels are highly elevated in brains of FTLD-tau patients suggesting that both β-arrestin1 and β-arrestin2 are elevated in the brains of patients with AD and FLTD. The current work also shows that when β-arrestin2 is overexpressed, tau levels become elevated. The data indicate that β-arrestin2 reduces tau clearance by impairing p62-mediated autophagy, a role carried out by the oligomerized form of β-arrestin2. Therefore, disclosed herein are β-arrestin oligomerization inhibitors that can be used to prevent β-arrestin oligomerization and therefore the accumulation of tau in cells, i.e. tauopathy. Also disclosed are methods of treating a tauopathy in a subject that involve administering to the subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor disclosed herein.

US Patent:

20180250266, Sep 6, 2018

Filed:

Nov 24, 2017

Appl. No.:

15/821984

Inventors:

- Seoul, KR
MINYOUNG KIM - Incheon, KR
Youngsu LIM - Jeollabuk-do, KR
DAEHYUN HA - Seoul, KR
Young Yiul LEE - Seoul, KR
Buom Yong RYU - Gyeonggi-do, KR
Vladimir Uversky - Tampa FL, US
Insung Na - Gyeonggi-do, KR
Yu Chen - Tampa FL, US
Arjan van der Vaart - Tampa FL, US

Assignee:

Industry-University Cooperation Foundation Hanyang University - Seoul

International Classification:

A61K 31/40
A61K 31/357
A61P 35/02

Abstract:

The present invention relates to a composition including an inhibitor against the function of an Mi-2/NuRD chromatin remodeling complex for inhibiting metastasis and preventing and treating cancer diseases, and more particularly, the composition may inhibit the MBD2-p66α (GATAD2A) interaction by means of the Mi-2/NuRD CRC function inhibitor, and thus is expected to be effectively used as a composition capable of inhibiting metastasis and preventing and treating cancer diseases.